BSEGodavari Drugs LtdMediumPositive
Announced Fri, 20 Mar · 18:34 IST

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kamala Jaju

Promoter Stake BuyOwnership Changes View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+7.8%1-day move
₹82.50
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+7.8+9.1+3.7+4.2+13.9+10.3+50.3+44.5+53.9+47.9
Up moveDown movePending
AI summary

Kamala Jaju, a promoter of Godavari Drugs Ltd, has acquired 3,00,000 convertible warrants through a preferential allotment on 18 March 2026. Before this, she held 9,10,000 equity shares representing 12.08% of the company. After the warrant acquisition, her total holding (shares + warrants) rises to 12,10,000, which works out to 8.99% of the expanded share capital and 9.69% on a fully diluted basis. The company's total equity share capital expanded from Rs. 7.53 crore to Rs. 10.13 crore following this preferential issue. The warrants, once exercised, will further increase her stake in the company.

Likely market impact

This signals continued promoter confidence and commitment of fresh capital into the company. For shareholders, the preferential issue dilutes existing equity by about 34%, and the promoter's effective voting percentage drops on total capital basis (12.08% to 8.99%), though it strengthens her absolute economic interest on a diluted basis.